➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Express Scripts
Baxter
McKesson
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Litigation Details for IMMUNEX CORPORATION v. SANDOZ INC. (D.N.J. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Biologic Drugs cited in IMMUNEX CORPORATION v. SANDOZ INC.
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for IMMUNEX CORPORATION v. SANDOZ INC. (D.N.J. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-02-26 1 Complaint the ’522 patent”), 7,915,225 (“the ’225 patent”), 8,119,605 (“the ’605 patent”), and 8,722,631 (“the …arthritis. The ’225 patent, the ’605 patent, and the ’631 patent (“the Psoriasis Patents”), owned by Immunex… The asserted patents are United States Patent Nos. 8,063,182 (“the ’182 patent”), 8,163,522 (“the…the ’631 patent”) (collectively, “the patents-in-suit”). 11. Roche is the owner of the ’182 …to the ’182 and ’522 patents, an exclusive sublicense) to the asserted patents. 14. On September External link to document
2016-10-28 125 Redacted Document the ‘522 patent”), 7,915,225 (“the ‘225 patent”), 8,119,605 (“the ‘605 patent”), and 8,722,631 (“the …of U.S. Patent Nos. 8,063,182 (“the ‘182 patent”); 8,163,522 (“the ‘522 patent”); 7,915,225 (“the ‘225…arthritis. The ‘225 patent, the ‘605 patent, and the ‘631 patent (“the Psoriasis Patents”), owned by Immunex…. The asserted patents are United States Patent Nos. 8,063,182 (“the ‘182 patent”), 8,163,522 (“the…‘225 patent”); 8,119,605 (“the ‘605 patent”); and 8,722,631 (“the ‘631 patent”). 11. Roche External link to document
2016-12-01 133 Markman Opening Brief ’225 Patent US Patent No. 7,915,225 ’605 Patent US Patent No. 8,119,605 ’631 Patent…Wall, Ph.D. ’182 Patent US Patent No. 8,063,182 ’522 Patent US Patent No. 8,163,522 ’…Reference Patent Office United States Patent and Trademark Office PTAB Patent Trial …owns the patent granted on this novel fusion protein (“the ’182 Patent”), as well as the patent that claims… ’605, and ’631 Patents”) (the “Immunex Patents”). Roche licensed the Roche Patents to Immunex, which External link to document
2016-12-01 134 Markman Opening Brief 225 patent U.S. Patent No. 7,915,225605 patent U.S. Patent No. 8,119,605… ’182 patent U.S. Patent No. 8,063,182522 patent U.S. Patent No. 8,163,5228,119,605631 patent U.S. Patent No. 8,722,631 Submarine patents The ’182 and ’522…’522 patents Psoriasis patents The ’225, ’605, and ’631 patents IgG Immunoglobulin…are two sets of patents at issue here: the ’182 and ’522 patents, or “submarine patents” (Bogad Exs. 1 External link to document
2018-10-30 651 Corrected Post-Trial Brief Obviousness-Type Double Patenting References Finck patents U.S. Patent Nos. 7,915,225 [JTX-39], 8,119,605… Patents/Patent Publications ’182 patent U.S. Patent No. 8,063,182 [JTX-1…1] ’522 patent U.S. Patent No. 8,163,522 [JTX-2] Roche Patents ’182 patent and ’522 patent… ’690 U.S. Patent No. 5,605,690 [JTX-42] patent ’279 patent U.S. Patent No. 5,610,279 …Roche Patents expire after the Finck patents is that the law defining the term of patents changed—the External link to document
2019-08-07 688 Pretrial Order double-patenting reference families: U.S. Patent Nos. 7,915,225 ("Finck '225 patent"), …list also included U.S. Patent Nos. 7,915,225 ("the Finck '225 patent"), 8,119,605 ("…JTX-39 U.S. Patent No. 7,915,225 JTX-40 U.S. Patent No. 8,119,605 JTX-41…double patenting. . . . A later patent claim is not patentably distinct from an earlier patent claim if…631 patents were reference patents to the Patents-in­ Suit, the Asserted Claims of the Patents-in-Suit External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Mallinckrodt
Merck
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.